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Abstract
Background: Hospitalized patients in critical care settings are at risk for bloodstream infections (BSI). Most BSIs
originate from a central line (CL), and they increase length of stay, cost, and mortality. Open infusion containers
may increase the risk of contamination and administration-related (CLAB) because they allow the entry of air into
the system, thereby also providing an opportunity for microbial entry. Closed infusion containers were designed to
overcome this flaw. However, open infusion containers are still widely used throughout the world.
The objective of the study was to determine the effect of switching from open (glass, burettes, and semi-rigid)
infusion containers to closed, fully collapsible, plastic infusion containers (Viaflex®) on the rate and time to onset of
central line-associated bloodstream infections CLABs.
Methods: An open label, prospective cohort, active healthcare-associated infection surveillance, sequential study
was conducted in four ICUs in Mexico. Centers for Disease Control National Nosocomial Infections Surveillance
Systems definitions were used to define device-associated infections.
Results: A total of 1,096 adult patients who had a central line in place for >24 hours were enrolled. The CLAB rate
was significantly higher during the open versus the closed container period (16.1 versus 3.2 CLAB/1000 central line
days; RR = 0.20, 95% CI = 0.11-0.36, P < 0.0001). The probability of developing CLAB remained relatively constant in
the closed container period (1.4% Days 2-4 to 0.5% Days 8-10), but increased in the open container period (4.9%
Days 2-4 to 5.4% Days 8-10). The chance of acquiring a CLAB was significantly decreased (81%) in the closed
container period (Cox proportional hazard ratio 0.19, P < 0.0001). Mortality was statistically significantly lower
during the closed versus the open container period (23.4% versus 16.1%; RR = 0.69, 95% CI = 0.54-0.88, P < 0.01).
Conclusions: Closed infusion containers significantly reduced CLAB rate, the probability of acquiring CLAB, and
mortality.
Background
Patients in hospitals are at risk for bloodstream infec-
tions (BSI), mainly in critical care settings. Most BSIs
originate from a central line (CL) [1], and they increase
length of stay, cost, and mortality [2-14].
During setup, admixture preparation, and administra-
tion [15,16], there is a high risk of contamination of
intravenous (IV) fluids. When the system is vented, as is
mandatory with open infusion containers, there are
extra risks of extrinsic contamination.
Both open and closed infusion containers are used
worldwide [5,17]. Open infusion containers consist of
rigid (glass, burette) containers or semi-rigid plastic con-
tainers that must admit air (air filter or needle) to empty
the contents (Figures 1, 2, 3). Closed infusion containers
consist of fully collapsible plastic containers that do not
require or use any external vent (air filter or needle) to
empty the solution, and have self-sealing injection ports
(Figure 4).
Standard practice incorporates the use of closed sys-
tems to prevent healthcare-associated infections (e.g.,
catheter-associated urinary tract infections [CAUTI])
[18], ventilator-associated pneumonia [VAP] [19], surgi-
cal site infections [20], and central line-associated-
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countries have reported outbreaks of infusion-related
CLAB traced to contamination of infusate in open infu-
sion systems [15,21-26]. Extrinsic or in-use contamina-
tion plays the most important role in bacterial
contamination of the infusion system [26-28].
In Argentina, switching from open, semi-rigid plastic
infusion containers to closed, fully collapsible plastic
infusion containers was cost effective and resulted in a
64% CLAB rate reduction [17]. However, the open con-
tainers studied were limited to semi-rigid plastic con-
tainers, and time to CLAB was not studied in Argentina.
In this study conducted in Mexico, 3 types of open
infusion containers (glass bottles, burettes, and semi-
rigid plastic) were utilized. A time-to-onset of CLAB
analysis was also included to evaluate the probability of
developing CLAB.
We report the results of a prospective, sequential
study undertaken to determine the impact of switching
from an open (glass bottles, burettes, and semi-rigid
plastic) to a closed, fully collapsible plastic infusion con-
tainer (Viaflex®) on the rate and time-to-onset of CLAB
in Mexico.
Methods
Setting
Three hospitals in Mexico City participated in the study:
General Hospital, Century XXI Specialties Instituto
Mexicano del Seguro Social (IMSS) Hospital, and
Mancera IMSS Hospital. In accordance with recommen-
dations [29], each has an active infection control pro-
gram, composed of a physician trained in internal
medicine and infectious diseases, and an infection con-
trol nurse. General Hospital is a public hospital, while
Century XXI Specialties IMSS Hospital and Mancera
IMSS Hospital are social security hospitals. The four
intensive care units (ICUs) in the study centers operate
at the highest level of complexity in Mexico (Level IV),
providing treatment for patients who have undergone
open-heart surgery, neurosurgery, gastrointestinal or
orthopedic surgery, as well as patients with trauma or
serious medical illnesses.
The study was conducted in accordance with the
Declaration of Helsinki. The study protocol was
approved by the ethics committee at General Hospital
and Century XXI Specialties IMSS Hospital. Approval
was not required by Mancera IMSS Hospital, as study
specific procedures did not exceed the scope of standard
medical care.
A subject informed consent letter, which detailed
information regarding adverse effects, was approved by
the ethics committee at General Hospital. However, sub-
ject informed consent was not required at either Cen-
tury XXI Specialties IMSS Hospital or Mancera IMSS
Hospital, as the study did not disclose the patient’sc o n -
fidentiality or privacy and did not involve any additional
risks beyond the usual medical interventions performed
in the participating ICUs.
Figure 1 Open Infusion Container - Glass container with air
filter.
Figure 2 Open Infusion Container - Semi-rigid container with
air filter.
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Patients who had a CL in place for >24 hours were
enrolled from each of the study ICUs. A trained nurse
prospectively recorded on case report forms the patient’s
gender, average severity-of-illness score (ASIS) on ICU
entry [30], device utilization, antibiotic exposure, and all
active infections identified while in the ICU. The deci-
sion to obtain blood cultures was made independently
by the patient’s physicians. Standard laboratory methods
were used to identify microorganisms recovered from
positive blood cultures [31].
Definitions
United States Centers for Disease Control National
Nosocomial Infections Surveillance Systems (CDC-
NNIS) program definitions were used to define device-
associated infections: CLAB (both laboratory-confirmed
infection and clinical primary nosocomial sepsis), cathe-
ter-associated urinary tract infection CAUTI, and venti-
lator-associated pneumonia VAP [32].
An open infusion container was defined as a rigid
(glass, burette) or semi-rigid plastic container that must
admit air to empty (air filter or needle). A closed infu-
sion container was defined as a fully collapsible, plastic
container that does not require or use any external vent
(air filter or needle) to empty the solution, and has
injection ports that are self-sealing.
Study Design
Active surveillance for CLAB and compliance with
infection control practices continued throughout the
study using CDC-NNIS methodologies, definitions, and
criteria [30]. The open container period lasted 6 months
(December 2002 to May 2003) at General Hospital, 5
months (February 2003 to June 2003) at Century XXI
Specialties IMSS Hospital, and 4 months (April 2003 to
July 2003) at Mancera IMSS Hospital. The closed con-
tainer period lasted 6 months (June 2003 to November
2003), 5 months (July 2003 to November 2003), and 4
months (August 2003 to November 2003), respectively.
Baxter Viaflex®, a fully collapsible plastic closed infu-
sion container, was used during the closed container
period. Commercially available open infusion containers
(glass container, semi-rigid plastic container, and burette
products) were used during the open container period.
Protocol specified target hand hygiene (HH) and CL
care compliance was set at ≥70% and ≥ 95%, respec-
tively. We assessed HH (which included the use of alco-
hol based hand rub at one hospital) compliance [33],
placement of gauze on CL insertion sites, condition of
gauze dressing (absence of blood, moisture, and gross
soilage; occlusive coverage of insertion site) [34,35], and
documentation for date of CL insertion. A research
nurse observed healthcare workers (physicians, nurses,
and paramedical staff) three times per week across all
work shifts and recorded information on a standard
form. In addition, we conducted active surveillance for
other common healthcare-acquired infections such as
VAP and CAUTI. Mortality data also were collected.
Data Analysis
Outcomes measured during the open and closed con-
tainer periods included the incidence density rate of
CLAB (number of cases/1000 CL days) and time to
CLAB. Chi-square analyses for dichotomous variables
and t-test for continuous variables were used to analyze
baseline differences between periods. Relative risk (RR)
Figure 3 Open Infusion Container - Burette with air filter.
Figure 4 Closed Infusion Container - Fully collapsible plastic
container without air filter.
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determined for all outcomes. Time to first CLAB was
analyzed using a log-rank test and is presented graphi-
cally using Kaplan-Meier curves. In addition, simple life
table conditional probabilities are presented graphically
to help explain the changing risk of infection over time
(Figure 5).
Results
During the study, 1096 patients were enrolled, 548 dur-
ing the open container period and 548 during the closed
container period. Patients in both periods were statisti-
cally similar regarding patient demographics, underlying
illness (except for endocrine diseases, cardiac failure,
angina pectoris, chronic obstructive pulmonary disease,
hepatic failure, and presence of previous infection),
length of stay, ASIS, device utilization, and antibiotic
usage (Table 1).
No new infection control interventions, training pro-
grams, products or technologies were introduced during
the study periods and all of the investigators, key study
personnel, classifications, and diagnostics techniques
remained constant throughout the entire study. A lead-
in period of at least 3 months duration was conducted
to standardize HH and CL care compliance practice.
Compliance with HH during both periods was above
70% (81.0% and 74.7% during the open and closed con-
tainer periods, respectively; RR = 0.92; 95% CI = 0.90 -
0.95).
Presence of gauze at CL site was 99.2% and 99.0%
during the open and closed container periods, respec-
tively (RR = 1.00; 95% CI = 0.99 - 1.00). Correct condi-
tion of gauze was 98.3% and 97.9% during the open and
closed container periods, respectively (RR = 1.00; 95%
CI = 0.99 - 1.00). Presence of the date at the CL inser-
tion site/administration set was 100% during both the
open and closed container periods.
The incidence density rate and percentage of patients
with CLAB were both significantly lower in the closed
container period compared to the open container period
(Table 2). The majority of laboratory confirmed CLAB
isolates in both the open (53.3%, 16/30) and closed
(66.6%, 4/6) infusion container period were Gram-posi-
tive; Gram-negative isolates represented 43.3% (13/30)
in the open container period and 33.3% (2/6) in the
closed container period. The distribution of microorgan-
isms for both container periods is shown on Table 3.
In this study, we examined the timing of when the
first CLAB was acquired comparing the open and closed
container periods (Figure 5). The majority (62%) of
patients had a CL in place for ≤4 days. When examining
three-day intervals, the conditional probability of acquir-
ing a CLAB in the closed container period was observed
to be relatively constant (1.4% at Days 2-4 to 0.5% at
Days 8-10). In the open container period, the condi-
tional probability of acquiring a CLAB was higher in
each three-day interval compared to the corresponding
three-day interval in the closed container period. The
conditional probability of acquiring a CLAB in the open
container period ranged from 4.9% at Days 2-4 to 5.4%
at Days 8-10.
Overall, the chance of a patient acquiring a CLAB
decreased significantly-by 81%- in the closed container
period (Cox proportional hazard ratio 0.19, P < 0.0001).
There was no statistically significant difference
between the two periods with respect to incidence of
CAUTI or VAP rate (Table 2).
Mortality during the closed container period (16.1%)
was statistically significantly lower than during the open
container period (23.4%) (RR = 0.69; 95% CI = 0.54 -
0.88; P = 0.002) (Table 2).
Discussion
Critically ill patients commonly require CL access for
administration of large volumes of IV fluid, medications,
blood products, or for hemodynamic monitoring. All of
these carry a greater risk of CLAB [4,5,10,11].
Studies have shown that CLABs increase length of
stay, cost, and attributable mortality [2,3,5,36]. In 2005,
Stone conducted a meta-analysis of all the cost studies
p u b l i s h e do v e raf i v e - y e a rp e r i o da n df o u n dt h a tt h e
average cost of one CLAB was $36,441 (US) [36]. Pre-
viously, Rosenthal et al in Argentina published that
CLAB resulted in an extra 12 days of hospitalization
and $4,888 (US) [3]. Similarly, Higuera et al reported
that CLAB in Mexico resulted in an extra six days of
hospitalization and $11,560 (US) [2].
Moreover, CLABs are apparently related to increased
attributable mortality: In an Australian study, CLABs
resulted in excess mortality of 12% [37], and in a study
from the United States, Pittet et al reported an
Figure 5 Cumulative probability of 1
st CLAB displayed by CL
days.
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Page 4 of 8Table 1 Patient demographics, underlying illness, length of stay, device utilization and antibiotic usage during the
two study periods
Open infusion container
N = 548
Closed infusion container
N = 548
RR 95% CI P-value
% (n/N) % (n/N)
Sex (Male) 43.8% (240/548) 48.0% (263/548) 1.10 0.96 - 1.25 0.16
Sex (Female) 56.2% (308/548) 52.0% (285/548) 0.93 0.83 - 1.03 -
Endocrine Disease 21.0% (45/214) 30.3% (154/508) 1.44 1.08 - 1.93 0.01
Cardiac Failure 27.1% (58/214) 42.5% (216/508) 1.57 1.23 - 2.00 <0.01
Angina Pectoris 2.8% (6/214) 10.0% (51/508) 3.58 1.56 - 8.22 <0.01
Cardiac Surgery 0.0% (0/214) 0.4% (2/508) - - 0.36
COPD 0.0% (0/214) 15.0% (76/508) - - <0.01
Cancer 4.2% (23/548) 4.2% (23/548) 1.00 0.57 - 1.76 1.0
Renal Impairment 4.7% (10/214) 7.5% (38/508) 1.60 0.81 - 3.15 0.17
Hepatic Failure 0.9% (2/214) 3.9% (20/508) 4.21 0.99 - 17.86 0.03
Abdominal Surgery 23.4% (128/548) 22.1% (121/548) 0.95 0.76 - 1.18 0.61
Thoracic Surgery 0.0% (0/214) 0.8% (4/508) - - 0.19
Trauma 0.0% (0/214) 1.2% (6/508) - - 0.11
Previous Infection 0.0% (0/214) 21.5% (109/508) - - <0.01
Stroke 0.0% (0/214) 1.0% (5/508) - - 0.15
Immunodeficiency 0.9% (2/214) 1.6% (8/507) 1.69 0.36 - 7.89 0.50
Urinary catheter 91.2% (500/548) 94.0% (515/548) 1.03 1.00 - 1.07 0.08
Mechanical ventilator 66.4% (364/548) 68.2% (374/548) 1.03 0.95 - 1.12 0.52
Mean ± SD Mean ± SD
ICU stay (days) 6.5 ± 6.56 7.1 ± 6.69 - - 0.13
Age (yrs) 54.1 ± 18.29 54.4 ± 18.58 - - 0.78
Severity-of-illness score 3.7 ± 0.90 3.8 ± 0.82 - - 0.45
CL utilization per patient (days) 6.7 + 7.35 7.4 + 7.54 - - 0.11
Mechanical ventilator utilization per patient (days) 4.3 ± 6.10 4.7 ± 6.61 - - 0.24
Urinary catheter utilization per patient (days) 6.0 ± 6.64 6.6 ± 6.65 - - 0.18
Defined daily dose Defined daily dose
Antibiotic use per 1000 days 1485 1540 - - 0.056
n, number of subjects with the characteristic present at baseline; N, total number of subjects with the with available (non-missing) results for the characteristic at
baseline.
Table 2 Incidence of CLAB, CAUTI, VAP, and mortality during the two study periods
Open infusion container
N = 548
Closed infusion container
N = 548
RR 95% CI P-value
CL days no. 3661 4055 - - -
CLAB no. 59 13 - - -
CLAB per 1000 CL days 16.1 3.2 0.20 0.11 - 0.36 <0.01
Percentage of patients with CLAB 10.8 2.4 0.22 0.12 - 0.40 <0.01
Urinary catheter days no. 3302 3590 - - -
CAUTI no. 30 36 - - -
CAUTI per 1000 catheter days 9.1 10.0 1.10 0.68 - 1.79 0.69
Mechanical ventilator days no. 2344 2592 - - -
VAP no. 66 71 - - -
VAP per 1000 mechanical ventilator days 28.2 27.4 0.97 0.70 - 1.35 0.87
Deaths no. 128 88 - - -
Percentage of patients who died 23.4 16.1 0.69 0.54 - 0.88 <0.01
no., number; CL, central line; CLAB, central line-associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated
pneumonia
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Page 5 of 8attributable mortality of 25% [38,39]. Rosenthal et al
likewise published an attributable mortality of 25% in a
study of CLABs in medical/surgical ICUs in Argentina
[12], and Higuera et al recently reported an attributable
mortality of 20% in a study of ICUs in Mexico [2].
CLAB can be easily prevented [40]. The efficacy of
simple interventions has been repeatedly documented in
randomized trials. These interventions include, but are
not limited to, mandating use of maximal barrier
[41,42], HH, skin antisepsis, catheter site dressing regi-
mens, catheter securement devices, and implementation
of outcome and process surveillance plus education and
performance feedback [34,35].
Contamination of infusate or catheter hubs have
resulted in epidemics of infusion-related CLAB [43]. It
is very rare in the United States to have intrinsic con-
tamination of parenteral fluids (microorganisms intro-
duced during manufacture) [43]. In addition, the risk of
extrinsic contamination of infusate during administra-
tion in the hospital has been reduced with widespread
use of closed infusion systems. However, open infusion
systems are still widely used throughout the world. A
high rate of CLAB was associated with use of open infu-
sion containers in this study, whereas there was a signif-
icant reduction in CLAB rate with use of a closed
infusion container. However, to date no regulations in
Mexico require the use of closed infusion systems.
Open infusion containers may increase the risk of
contamination and administration-related CLAB because
they allow the entry of air into the system, thereby also
providing an opportunity for microbial entry. The closed
infusion container that was investigated (a fully collapsi-
ble, plastic container not requiring or using any external
vent [air or needle] to empty and having self-sealing
ports) was designed to overcome this flaw. When infus-
ing intravenous solutions, it is important that the resi-
dual solution in the container after the infusion not
exceed 5% of the nominal volume in order to deliver
the correct dosage. Containers leaving more than this
amount, even if non-vented and theoretically closed,
may nevertheless be vented in practice by healthcare
workers who spike the container with a needle to ensure
delivery of the solution to the patient, thus introducing
an opportunity for contamination. Similarly, when
choosing a closed system for parenteral infusion, it is
important that the container enables a consistent and
even infusion rate throughout the administration pro-
cess without the assistance of a mechanical device like
an infusion pump, and that it maintains its integrity
during extreme usage conditions.
The probability of developing a CLAB was assessed in
three-day intervals during each period to evaluate the
effect of CLAB over time. It is useful to display and
assess the distribution of time of CL use across patients
in order to avoid being misled by a cross study compari-
son when comparing results of CLABs between studies.
A study with a preponderance of 2-4 CL days per
patient compared to a study with a preponderance of
10-12 CL days per patient would have vastly different
observed CLAB rates when a hazard function is not
constant - even when all other factors are identical (e.g.,
equal number of total CL days, similar patient popula-
tion, and identical study design and methodology).
We also examined the timing of when the first CLAB
was acquired comparing open versus closed infusion
containers. Prior investigation published in 2004 did not
include this additional analysis [17]. From this additional
analysis, we demonstrated that when using an open
infusion container, the risk of acquiring CLAB increases
over time. However, if the patient receives infusate via a
closed infusion container, the probability of acquiring a
CLAB remains relatively constant. The patient also
acquires a CLAB significantly later, suggesting that
closed infusion containers reduce risk of CLAB acquisi-
tion over time. Subsequently, the use of a closed infu-
sion containers could especially benefit those patients
with more severe illness who may require CLs for longer
periods of time. The delayed onset of CLAB may also
benefit patients with CLs early during the course of
treatment when their underlying illness might be most
severe.
Blinding the treatment assignment was not practical in
this study; however, this might have avoided the possible
selection bias that could occur in an open label, rando-
mized study. In an effort to minimize protocol
Table 3 Microbial profile of CLAB during the two study
periods
Microorganism Open infusion
container
Closed infusion
container
CULTURE DOCUMENTED
BSIs
30 6
Gram-positive bacteria, n (%) 16 (53.3%) 4 (66.6%)
Staphylococcus aureus 61
Coagulase-negative
staphylococci
93
Enterococci species 1 0
Gram-negative bacteria, n
(%)
13 (43.3%) 2 (33.3%)
Alcaligenes species 1 0
Enterobacter species 5 0
Klebsiella species 1 1
Proteus species 1 0
Acinetobacter species 2 0
Serratia species 1 1
Pseudomonas species 2 0
Yeasts, n (%) 1 (3.3%) 0
Candida species 1 0
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two infusion systems was also not implemented. Logisti-
cally it was easier to assure that patients received IV
fluids in the appropriate infusion containers when only
t h o s ec o n t a i n e r sw e r ep r e s e n ti nt h eI C U sd u r i n gt h e
specified open or closed container period of the study.
Subsequently, a time series, sequential design was imple-
mented. In order to minimize the effects of confounding
factors no new infection control interventions, training
programs, products or technologies were introduced
during the study periods and all of the investigators, key
study personnel, classifications and diagnostic techni-
ques remained constant throughout the study. In addi-
tion, HH and CL care compliance practices were
standardized during the lead-in period.
Another study limitation was that the study design did
not allow for determination of the epidemiologic
mechanisms responsible for the striking differences in
outcome (e.g., reduced contamination of infusate). In
spite of a reduction in HH compliance during the closed
infusion system phase, the CLAB rate improved.
In a separate study by Munoz et al (1997), infusions
were cultured at a second-level general teaching hospital
in Mexico wherein a 29.6% contamination rate was
found during the baseline period [23]. A 2% contamina-
tion rate was reported by Macias et al (1999) in a multi-
center cross-sectional study in Mexico; lapses in aseptic
technique, and breaks in the infusion system while
injecting IV medications were risk factors for in-use
contamination [15].
The CDC Healthcare Infection Control Practices
Advisory Committee (HICPAC) offers direction for the
prevention of CLAB by limiting manipulations of and
entry into running infusions. In addition, persons hand-
ling or entering an infusion should only do so after
implementing appropriate infection control measures
and with strict adherence to aseptic technique [42].
Conclusions
This study has demonstrated that the use of closed infu-
sion containers prevents CLAB and reduces mortality.
Hospitals that continue to use burettes and/or open
rigid or semi-rigid fluid containers (which must be
vented to allow ambient air entry and fluid egress)
should evaluate switching to closed, non-vented, fully
collapsible bags to reduce CLAB rates.
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